Table 2.
Ref.
|
Design
|
n
|
Technique
|
Neurolytic agent
|
Pain control (follow up)
|
Complications
|
Wiersema et al[6] | Retrospective | 30 | Bilateral | 3 mL bupivacaine (0.25%) + 10 mL ethanol (98%) | 88% (10 wk) | Diarrhea 13.3%, Pain 3.3% |
Gunaratnam et al[17] | Prospective | 58 | Bilateral | 3-6 mL bupivacaine (0.25%) + 10 mL ethanol (98%) | 78% (24 wk) | Pain 8.6% |
Levy et al[11] | Retrospective | 17 | Direct | 8 mL bupivacaine (0.25%) + 12 mL ethanol (99%) | 94% (2-4 wk) | Hypotension 35%, pain 41% and diarrhea 16% |
Sahai et al[9] | Prospective | 160 | Central vs Bilateral | 10 mL bupivacaine (0.5%) + 20 mL ethanol | 45.9% vs 70.5% (7 d). P < 0.05 | Bleeding 0.7% |
Sakamoto et al[18] | Retrospective | 67 | Broad vs bilateral | 3 mL lidocaine (1%) + 9 mL ethanol (98%) | Mean VAS scores 3.9 vs 2.5 (7 d) and 4.8 vs a 3.4 (30 d) P < 0.05 | None |
Wyse et al[7] | RCT | 48 | Bilateral vs analgesia | 10 mL bupivacaine (0.50%) + 20 mL ethanol | Likert scale reduction 28% (4 wk) + 60% (12 wk) P < 0.05 | None |
LeBlanc et al[10] | RCT | 50 | Central vs bilateral | 20 mL lidocaine (0.75%) + 10 mL ethanol (98%) | 69% vs 81% (61.9%)(14wk) | Hypotension 2% pain 36% |
Iwata et al[19] | Retrospective | 47 | Central, direct or bilateral | 2-3 mL bupivacaine + 20 mL ethanol | 68% (7 wk) | Hypotension 17%, diarrhea 23% and inebriation 8% |
Ascunce et al[20] | Retrospective | 64 | Bilateral | 10 mL lidocaine (1%) + 20 mL ethanol (98%) | 50% (1 wk). OR 15.61 of response if celiac ganglia was detected | Hypotension 2%, pain 2% and diarrhea 23% |
Wiechowska-Kozłowska et al[12] | Retrospective | 29 | Central vs bilateral | 2 mL lidocaine (2%) + 20 mL ethanol (98%) | 86% (1-2 wk) | Hypotonia 3.4%, pain 6.9% and diarrhea 10.3% |
Téllez-Ávila et al[21] | Retrospective | 53 | Central vs bilateral | 10 mL lidocaine (1%) + 10-20 mL ethanol (98%) | 48% vs 56% (4 wk) | Transitory pain 0% vs 3% |
Seicean et al[22] | Retrospective | 32 | Central | 10 mL lidocaine (1%) + 10-15 mL ethanol | 75% (2 wk) | None |
Doi et al[13] | RCT | 68 | Direct vs central | 1-2 mL bupivacaine (0.25%-0.5%) + 10-20 mL ethanol | 73.5% vs 45.5% (7 d) P < 0.05 | Hypotension 2.9% vs 6%, pain 29.4% vs 21.2% and diarrhea 5.9% vs 9.1%. No diferences |
Ishiwatari et al[16] | Retrospective | 22 | Direct or bilateral | 1-2 mL bupivacaine (0.5%) + 40-60 mL ethanol or 20-25 mL fenol | 83% (fenol) vs 69% (ethanol) (7 d) | Diarrhea 9%, hypotension 4.5%, pain 4.5% and inebriation 4.5% |
Hao et al[23] | Retrospective | 41 | Central or direct | 10 mL bupivacaine (2%) + 20 mL ethanol | Pain < 3 mo improve 84% (3 d), 96% (7 d) and 68% (90 d). Pain > 3 mo improve 75% (3 d), 81% (7 d) and 50% (90 d) | Hypotension 4.9% |
Minaga et al[14] | Retrospective observational | 112 | Broad ± direct | 3 mL lidocaine (1%) + 9 mL ethanol (98%) | Pain improvement 77. 7% (1 wk)+ 67.9% (4 wk) | Inebriation 8%, hypotension 4.5%, pain 3.6% and diarrhea 3.6% |
Levy et al[24] | RCT | 110 | Direct vs bilateral | 4 mL bupivacaine (0.25%) + 20 mL ethanol (99%) | Pain improvement 46.2% vs 40.4%. No changes on quality of life | Hypotension 11.7% vs 20%, diarrhea 10% vs 12.2%. Pain 8.3% vs 44.9% (P < 0.05) |
VAS: Visual analogue scale. RCT: Randomized clinical trial.